New drug combo for first-line treatment of PTCL
Part of Blood & lymphatic, Cancer clinical trials.
This clinical trial tests a new combination of two drugs (SHR2554 and liposomal mitoxantrone) as a first treatment for adults with certain types of peripheral T-cell lymphoma. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of a type of peripheral T-cell lymphoma (PTCL), such as PTCL not otherwise specified or follicular helper T-cell lymphoma.
- You have not received any previous cancer treatment for your lymphoma.
- You have at least one tumor that can be measured or seen on a scan (like a PET/CT or MRI).
- You are generally able to take care of yourself (ECOG score 0-2) and are expected to live at least 3 months.
- You do not have serious heart problems, and have not had chest radiation or taken mitoxantrone before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the drug SHR2554 as a maintenance therapy for people with peripheral T-cell lymphoma who responded well to their first chemotherapy. The goal is to help keep the cancer from coming back.
This trial tests a combination of two drugs—mitoxantrone hydrochloride liposome and enlonstobart—for people with peripheral T-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if the combination can shrink tumors and improve outcomes.
This trial is testing a combination of two targeted drugs (linperlisib and an EZH2 inhibitor) for people whose peripheral T-cell lymphoma has come back or not responded to previous treatment. The goal is to see if this new combination can help shrink tumors and slow the disease.
This trial tests a combination of two drugs (adebrelimab and SHR2554) for patients with T-cell or NK/T-cell lymphomas that have stopped responding to previous treatments. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug called SHR2554 (compared to chidamide) for T-cell lymphoma that has not responded to or come back after prior treatment. It's a Phase 3 study to see if the drug can help control the cancer.
This trial tests a combination of three drugs (zeprumetostat, azacitidine, and a liposomal form of mitoxantrone) for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the lymphoma.
Hear when a new PTCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.